Editor: Atta-ur-Rahman

Frontiers in Clinical Drug Research-Anti-Infectives

Volume 8

eBook: US $79 Special Offer (PDF + Printed Copy): US $145
Printed Copy: US $105
Library License: US $316
ISSN: 2452-3208 (Print)
ISSN: 2352-3212 (Online)
ISBN: 978-981-5039-42-9 (Print)
ISBN: 978-981-5039-41-2 (Online)
Year of Publication: 2021
DOI: 10.2174/97898150394121210801

Introduction

Frontiers in Clinical Drug Research – Anti infectives is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of infectious diseases. The scope of the book series covers a range of topics including the chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of infectious diseases. Reviews in this series also include research on multi drug resistance and pre-clinical / clinical findings on novel antibiotics, vaccines, antifungal agents and antitubercular agents. Frontiers in Clinical Drug Research – Anti infectives is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of anti infective drug discovery and epidemiology.

The eighth volume of this series presents comprehensive reviews of interest to readers interested in the treatment of inflammatory diseases, new antiviral agents and strategies, specific antiprotozoal drugs that work against leishmania and helminths, and a study on potential agents against American foulbrood in honey bees. The 7 reviews included in this volume are:

- Monoclonal antibodies as therapeutic agents for inflammatory diseases

- Pharmacotherapy of emerging antiviral agents

- Antiviral activity of vitamin D and COVID-19: current understanding

- Anti-infectives to combat leishmaniasis

- Anthelmintic drug discovery: current situation and future perspectives

- Therapeutic targets for emerging Zika virus infection and vaccines in clinical trials

- Agro-industrial waste: new source of raw material for the control of American foulbrood in honey bees

Audience: Pharmaceutical scientists, medical doctors, virologists, entomologists, epidemiologists

Preface

The 8th volume of Frontiers in Clinical Drug Research – Anti Infectives comprises seven chapters that cover several important topics including the role of monoclonal antibodies, emerging antiviral agents, and the current situation on antiparasitic drug discovery.

In chapter 1, Capela et al. discuss the role of monoclonal antibodies as therapeutic agents for inflammatory diseases. Doshi et al. explore the pharmacotherapy of emerging antiviral agents in chapter 2 of the volume. Al-Azzawi and Sakr discuss how vitamin D can be used as a preventive or treatment agent for COVID-19. Das et al., in chapter 4, present an overview of anti-infectives to combat leishmaniasis. Rayes et al., in chapter 5, summarize the current situation on antiparasitic drug discovery and discuss the use of C. elegans at the initial steps of drug development. In the next chapter, Kannan et al. discuss the emergence of the Zika virus and its detailed genome structure and replication cycle. Fuselli et al., in the last chapter of the volume, give an insight on agro-industrial waste, a new source of raw material for the control of American foulbrood in honey bees.

I would like to thank all the authors for their excellent contributions that should be of great interest. I would also like to thank the editorial staff of Bentham Science Publishers, particularly Mr. Mahmood Alam (Editorial Director of Bentham Science Publishers), Mr. Obaid Sadiq (In-charge Books Department), and Miss Asma Ahmed (Senior Manager Publications) for their support.

Atta-ur-Rahman, FRS
Kings College
University of Cambridge
Cambridge
UK